SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Soleno Therapeutics Inc (SLNO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent FDA approval for VYKAT XR, the first treatment for hyperphagia in Prader-Willi Syndrome, positions it well in a competitive market. Despite insider selling and a slight drop in pre-market, the stock's technicals, options sentiment, and analyst ratings suggest potential for growth. The investor's long-term horizon aligns with the company's strong commercial trajectory and expected revenue growth in 2026.
The stock shows mixed technical signals. The MACD is positively expanding, indicating bullish momentum, but the RSI is neutral at 51.86, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 34.288, and resistance is at 41.34. The stock has an 80% chance to gain 6.19% in the next month.
FDA approval for VYKAT XR as the first treatment for hyperphagia in Prader-Willi Syndrome.
Analysts maintain strong buy ratings with high price targets, indicating confidence in the company's commercial outlook.
Competitive advantage as competitors face challenges or halt trials.
Insider selling has increased significantly by 1314.42% over the last month.
Financial performance in Q4 2025 showed a significant drop in net income (-176.71% YoY) and EPS (-156.69% YoY).
In Q4 2025, revenue remained flat at $91.73 million YoY, but net income dropped significantly to $42.94 million (-176.71% YoY), and EPS fell to 0.72 (-156.69% YoY). Gross margin increased slightly to 99.06%.
Analysts maintain a positive outlook with buy ratings and high price targets (ranging from $85 to $110). They emphasize the company's strong commercial trajectory, expected FY26 revenue growth, and discounted valuation relative to its free cash flow profile.
